首款国产司美格鲁肽要来了?九源基因在财报中预计下半年获批

第一财经
26 Mar

2024年4月,九源基因在国内提交了司美格鲁肽治疗二型糖尿病(商品名是“吉优泰”)的上市申请,在国内诸多款司美格鲁肽生物类似药中拔得了头筹。   3月26日晚间,九源基因(02566.HK)公布了上市后首份年度业绩公告,2024年公司实现总收入13.69亿元,同比增长6.4%;净利润1.39亿元,同比增长15.7%。   九源基因已经形成骨科、代谢、肿瘤及血液四大治疗领域的产品布局,其中,代谢产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10